ClinicalTrials.gg
TerminatedNCT00494533TRUST-1Updated Jan 29, 2014

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension

A Phase 4 interventional study of Remodulin (treprostinil sodium) in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Terminated at 14 sites in India. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-01-29.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Why this study was terminated
Safety issues related to outpatient intravenous infusion in India

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
15th of 44
45 · median 32
Started
2005
with 2 others
Phase 4
14 of 44
1 open now
Registered
6th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 15th largest by enrollment, is one of 3 that started in 2005, is one of 14 in phase 4, and was the 6th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human immunodeficiency virus (HIV) infection or collagen vascular disease).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • prostacyclin analogue
  • intravenous
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients Must

  1. Between 16- 75 years of age.
  2. Male or, if female, physiologically incapable of childbearing or utilizing .
  3. Have current diagnosis of symptom-limited Functional Class III/IV PAH that is:

    • PPH ("idiopathic" or familial PAH); or
    • PAH associated with collagen vascular disease (confirmed by antinuclear antibody titer or acceptable test); or
    • PAH associated with infection (confirmed by serological test).
  4. If HIV positive, have ≥ 200 at baseline and receiving current SOC anti-retroviral or effective medication for HIV infection.
  5. Optimally treated with conventional PH therapy and clinically stable for at least 1 month prior to baseline.
  6. Have ventilation/perfusion scan, contrast-enhanced CT scan, or pulmonary angiogram after onset of PAH that rules out pulmonary embolism.
  7. Have cardiac catheterization in last 3 months (or at Baseline) showing:

    • PAPm > 35 mmHg (at rest) \&
    • PCWPm (or LV end diastolic pressure) \< 16 mmHg \&
    • PVR > 5 mmHg/L/min.
  8. Have echocardiogram in last 3 months consistent with PH, specifically:

    • evidence of RV hypertrophy or dilation \&
    • evidence of normal LV function \&
    • absence of mitral valve stenosis.
  9. Have chest radiograph consistent with PH performed in last 3 months. Radiograph must show clear lung fields or no more than patchy interstitial infiltrates.
  10. Unless , able to receive one of following anticoagulants: warfarin to achieve between 1.5-2.5 or heparin to produce aPTT between 1.3-1.5 times control, unless higher levels clinically indicated.
  11. Mentally and physically capable of learning to administer Study Drug using ambulatory intravenous infusion pump and central venous access, or have trained caregiver.
  12. If on , receiving stable dose of 20 mg/day of prednisone (or equivalent dose of another steroid) for at least 1 month prior to entry.

Exclusion Criteria: Patients must not:

  1. Nursing or pregnant (women of have negative pregnancy test).
  2. Have had new type of chronic therapy (including but not limited to oxygen, different category of vasodilator, diuretic, digoxin) for PH, except for anticoagulants, added in last month.
  3. Be scheduled for heart-lung transplant.
  4. Have any PH medication except for anticoagulants discontinued in week prior to study entry.
  5. Have received any chronic prostaglandin or prostaglandin analogue (including intravenous/inhaled/oral: epoprostenol, iloprost, beraprost, etc.), any phosphodiesterase inhibitor therapy such as sildenafil, or any endothelin antagonist therapy such as bosentan, in past 30 days.
  6. Have PH associated with chronic thromboembolic disease; or chronic obstructive lung diseases or hypoxemia; or evidence of significant parenchymal lung disease as evidenced by PFTs in last 3 months as follows (any one of following):

    • TLC \< 60% (predicted) or high resolution CT documenting diffuse interstitial fibrosis or alveolitis
    • /FVC ratio \< 50%
  7. Have Portal Hypertension.
  8. Have history of uncontrolled Sleep Apnea, defined as oxygen desaturation less than 90% at night, in past 3 months.
  9. Have history of left-sided heart disease including:

    • Aortic or mitral valve disease or
    • Pericardial constriction or
    • Restrictive or congestive cardiomyopathy; or have evidence of current left-sided heart disease defined by:
    • PCWPm or LV end diastolic pressure > 16 mmHg or
    • \< 40% by MUGA, angiography or echocardiography or
    • LV Shortening Fraction \< 22% by echocardiography or
    • Symptomatic coronary disease (demonstrable ischemia).
  10. Have any disease other than HIV or connective tissue disease associated with PH (e.g. sickle cell anemia, schistosomiasis).
  11. Have active AIDS or tuberculosis.
  12. Have musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease thought to limit ambulation, or connected to machine which is not portable.
  13. Have baseline exercise capacity of \<50 m or >325 m as measured by 6-Minute Walk Test.
  14. Have uncontrolled systemic hypertension as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg.
  15. Have used prescription appetite suppressants in 3 months of study entry.
  16. Have chronic renal insufficiency defined by creatinine >2.5 mg/dL or requiring dialysis.
  17. Receiving an drug (other than acute challenge with epoprostenol), have in place an investigational device, or have participated in investigational drug/device study in past 30 days.
  18. Have presence of any physiological or mental condition which contraindicates administration of Remodulin.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)
06

What researchers measure

Primary outcomes

  1. Six-minute walk distance

    Placebo-corrected change in 6-minute walk distance from Baseline to Week 12.

    Time frame: Twelve Weeks

Secondary outcomes

  1. Borg Dyspnea Score

    The Bord dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the six-minute walk test (6MWT). The Borg dyspnea score was assessed immediately following the 6MWT. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).

    Time frame: Twelve Weeks

  2. Dyspnea-Fatigue Index

    The dyspnea-fatigue index was assessed at Baseline, Weeks 1, 4, 8 ans 12. Each of the three components of the dyspnea-fatigue index were rated on a scale of 0 to 4, with 0 being the worst condition and 4 being the best condition for each component. The dyspnea-fatigue index is computed by summing the three component scores.

    Time frame: Twelve weeks

  3. NYHA Functional Class

    Changes from Baseline in NYHA Functional Class will be summarized and compared between treatment groups at Weeks 1, 4, 8 and 12.

    Time frame: Twelve Weeks

  4. Clinical Worsening

    Clinical worsening was defined as worsening PAH resulting in death, transplant, hospitalization, necessity to unblind for rescue therapy, or an inability to physically perform the walk assessment. Incidence of clinical worsening and the time from Baseline to clinical worsening will be compared between treatment groups.

    Time frame: Twelve Weeks

  5. Combined Walk and Borg Dyspnea Score

    The intent of the Six-Minute Walk Test is to determine how much patients can do during the course of carrying out activities of daily living. However, the capacity of patients to function is determined not only by what they can do when they exert themselves to the fullest, but also by how they feel when they are carrying out their usual activities of daily living. It is therefore important not only to look at the distance traversed during the unencouraged 6-minute walk but also the symptoms experienced at the end of the effort. To do so, walk distances and Borg Scores from the Week 12 Six-Minute Walk Test were simultaneously compared between treatment groups.

    Time frame: 12 Weeks

07

Study locations

14 sites
  • SAL Hospital & Medical Institute
    Ahmedabad, India
  • Narayana Hrudayalaya Inst. Of Cardiac Sciences
    Bangalore, India
  • Apollo Hospitals
    Chennai, India
  • K. S. Hospital
    Chennai, India
  • Sri Ramachandra Medical College
    Chennai, India
  • Medwin Heart Institute
    Hyderabad, India
  • Yashoda Super Specialty Hospital
    Hyderabad, India
  • Apollo Gleneagles Hospital
    Kolkata, India
  • KMC Hospital
    Mangalore, India
  • Kasturba Medical College
    Manipal, India
  • KEM Hospital
    Mumbai, India
  • G. B. Pant Hospital & Maulana Azad Med. College
    New Delhi, India
  • Ruby Hall Clinic
    Pune, India
  • Krishna Institute of Medical Sciences
    Secunderabad, India
08

References and documents

Publications

  • Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ; TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010 Feb;29(2):137-49. doi: 10.1016/j.healun.2009.09.005. PubMed 20022264 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 29, 2007
Start
Mar 2005
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Jan 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00494533
Collaborators
Asian Clinical Trials
Responsible party
Sponsor
First posted
Jun 29, 2007
Start date
Mar 2005
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Jan 29, 2014

Study contacts

Michael Wade, Ph.D.
study director · United Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion